Targeting Higher Levels of Tau Protein in Ukrainian Patients with Wilson’s Disease
Open Access
- 27 March 2019
- journal article
- research article
- Published by Springer Nature in Neurology and Therapy
- Vol. 8 (1) , 59-68
Abstract
Introduction Wilson’s disease (WD) is a rare genetic disorder of copper metabolism in which impaired copper homeostasis may enhance amyloid aggregation and trigger neurodegeneration. Tau protein is a highly soluble microtubule-associated phosphoprotein that plays a significant role in microtubule stabilization; it is also a critical component of neurotoxic degenerative mechanisms. Tau has been shown to be involved in neuronal degeneration and axonal damage, and impaired copper metabolism has been shown to be involved in copper intoxication and thus associated with the processes of neurodegeneration and cellular damage. We have therefore investigated tau protein as a potential marker of axonal impairment and neurodegeneration. Methods Patients with WD (n = 47; mean age ± standard deviation [SD] 30.19 ± 7.87 years; mean disease duration : 10.06 ± 3.9 years) and healthy controls (HC; n = 30; mean age 29.6 ± 4.73 years) were tested for serum tau protein levels using an enzyme-linked immunosorbent assay method. All patients were receiving a stable penicillamine dose as ongoing therapy. Results Patients with WD had a higher mean tau protein level than did the HC (221.7 ± 135.1 vs. 71.14 ± 20.56 pg/mL, p < 0.0001). Patients with WD also had abnormally high serum tau protein levels (t statistic 6.047, 95% confidence interval − 218.2 to − 95.86) in both the cerebral and hepatocerebral forms of WD, with patients having the cerebral form showing a tendency toward higher tau levels. We found that tau protein did not differ according to gender, disease duration, age at disease onset, ceruloplasmin serum level and copper serum level. Conclusion This study provides novel data revealing that high tau protein levels in WD patients could be a potential biomarker for axonal impairment and possible neuronal damage due to tau protein, leading to neurodegeneration in WD.Keywords
This publication has 38 references indexed in Scilit:
- Penicillamine Increases Free Copper and Enhances Oxidative Stress in the Brain of Toxic Milk MicePLOS ONE, 2012
- Animal models reveal role for tau phosphorylation in human diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2010
- Recent advances in our understanding of neurodegenerationJournal of Neural Transmission, 2009
- Cerebrospinal fluid total tau protein levels in patients with multiple sclerosisActa Neurologica Scandinavica, 2007
- Wilson's DiseaseSeminars in Neurology, 2007
- Microtubule-associated protein tau as a therapeutic target in neurodegenerative diseaseExpert Opinion on Therapeutic Targets, 2007
- Alzheimer's diseaseThe Lancet, 2006
- The CSF levels of total-tau and phosphotau in patients with relapsing-remitting multiple sclerosisJournal of Neural Transmission, 2005
- Role of Tau Protein in Both Physiological and Pathological ConditionsPhysiological Reviews, 2004
- Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulinJournal of Molecular Biology, 1977